Introduction:Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has improved the life expectancy of these patients. However, TKIs have been related to an increase in cardiovascular events. These occur especially in patients who already had cardiovascular risk factors (CVRF). Material and methods: An observational cross-sectional study of patients with CML under treatment with TKI was conduced. The prevalence of CVRF, target organ damage and subclinical and symptomatic atherosclerotic cardiovascular disease (ASCVD) was studied. Results: 73 patients were included. 63.01% were male. The median age was 56 years 50). 47.95% had high blood pressure, 17.33% diabetes mellitus, 40.79% dyslipidemia, 50.68% overweight, 26.03 obesity and 21.92% were smokers. 19.20% presented microalbuminuria, 8.20% left ventricular hypertrophy and 19.18% chronic kidney disease. 32.90% had high values of hsCRP and 26% high values of pulse wave velocity. 11.07% had ASCVD. Patients treated with nilotinib had a higher prevalence of dyslipidemia, smoking, peripheral arterial disease, and ASCVD. Conclusions: The prevalence of CVRF was higher than that described in the general Spanish population. Patients treated with nilotinib had a higher prevalence of uncontrolled hypertension, dyslipidemia, smoking, peripheral arterial disease, and established atherosclerotic cardiovascular disease than patients treated with imatinib and dasatinib.
Sin embargo, los ITC se han relacionado con un incremento en los eventos cardiovasculares que se producen fundamentalmente en pacientes que ya presentaban factores de riesgo cardiovascular (FRCV). Material y métodos: Estudio observacional, descriptivo y transversal de pacientes con LMC en tratamiento con ITC. Se estudió la prevalencia de FRCV, lesión de órgano diana y enfermedad cardiovascular aterosclerótica (ECVA) subclínica y sintomática.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.